TOP TEN perturbations for 38823_s_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38823_s_at
Selected probe(set): 202693_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38823_s_at (202693_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary)
Relative Expression (log2-ratio):-5.380599Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, pleomorphic rhabdomyosarcoma, adult type of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary)
Relative Expression (log2-ratio):-4.969903Number of Samples:6 / 5
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, fibromyxosarcoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, fibromyxosarcoma of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary)
Relative Expression (log2-ratio):-4.544504Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, NOS of the soft tissue (subcutaneously implanted). |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary)
Relative Expression (log2-ratio):-4.487912Number of Samples:6 / 2
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, liposarcoma, well differentiated type; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, liposarcoma, well differentiated type of the soft tissue (subcutaneously implanted). |
R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample
Relative Expression (log2-ratio):-3.8085728Number of Samples:2 / 4
| Experimental | R547 study 1 (24h) |
| Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 μmol/L. ATC code:--- | |
| Control | vehicle (DMSO) treated DU145 cell sample |
| Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours. |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-3.7949333Number of Samples:3 / 3
| Experimental | echinomycin study 1 |
| Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
| Control | deferoxamine study 5 |
| Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
Sjogren's syndrome study 2 (pSS) / Sjogren's syndrome study 2 (non-pSS)
Relative Expression (log2-ratio):3.5818768Number of Samples:7 / 14
| Experimental | Sjogren's syndrome study 2 (pSS) |
| Incisional biopsy of one parotid gland of patients who fulfilled the 2002 AECG criteria for primary Sjogren's syndrome (pSS). Patients were at least 21 years old. | |
| Control | Sjogren's syndrome study 2 (non-pSS) |
| Incisional biopsy of one parotid gland of patients with Sicca-syndrome who did not fulfill the 2002 AECG criteria for primary Sjogren's syndrome (non-pSS Sicca). Patients were at least 21 years old. |
expO lung cancer study 1 (neuroendocrine carcinoma; primary) / expO lung cancer study 1 (adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):-3.441514Number of Samples:6 / 3
| Experimental | expO lung cancer study 1 (neuroendocrine carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with neuroendocrine carcinoma. | |
| Control | expO lung cancer study 1 (adenosquamous carcinoma; primary) |
| Primary tumor tissue samples obtained from the lung of patients with adenosquamous carcinoma. |
connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary)
Relative Expression (log2-ratio):-3.2273703Number of Samples:6 / 3
| Experimental | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, synovial sarcoma, spindle cell; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, synovial sarcoma, spindle cell of the soft tissue (subcutaneously implanted). | |
| Control | connective/soft tissue cancer study 1 (PDX; connective and soft tissue, malignant peripheral nerve sheath tumor; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary connective and soft tissue, malignant peripheral nerve sheath tumor of the soft tissue (subcutaneously implanted). |
engineered skin substitute study 2 (late) / engineered skin substitute study 1 (late)
Relative Expression (log2-ratio):-3.1795511Number of Samples:5 / 3
| Experimental | engineered skin substitute study 2 (late) |
| Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice. | |
| Control | engineered skin substitute study 1 (late) |
| Human skin substitutes tissue samples collected after 14 days in culture. |